O	0	7	CEREBEL
O	8	9	(
O	9	18	EGF111438
O	18	19	)
O	19	20	:
O	21	22	A
O	23	28	Phase
O	29	32	III
O	32	33	,
O	34	44	Randomized
O	44	45	,
O	46	50	Open
O	50	51	-
O	51	56	Label
O	57	62	Study
O	63	65	of
B-intervention	66	75	Lapatinib
I-intervention	76	80	Plus
I-intervention	81	93	Capecitabine
O	94	100	Versus
B-control	101	112	Trastuzumab
I-control	113	117	Plus
I-control	118	130	Capecitabine
O	131	133	in
B-eligibility	134	142	Patients
I-eligibility	143	147	With
I-eligibility	148	153	Human
I-eligibility	154	163	Epidermal
I-eligibility	164	170	Growth
I-eligibility	171	177	Factor
I-eligibility	178	186	Receptor
I-eligibility	187	188	2
I-eligibility	188	189	-
I-eligibility	189	197	Positive
I-eligibility	198	208	Metastatic
I-eligibility	209	215	Breast
I-eligibility	216	222	Cancer
O	222	223	.

O	224	231	CEREBEL
O	232	240	compared
O	241	244	the
O	245	254	incidence
O	255	257	of
O	258	261	CNS
O	262	272	metastases
O	273	275	as
O	276	281	first
O	282	286	site
O	287	289	of
O	290	297	relapse
O	298	300	in
O	301	309	patients
O	310	314	with
O	315	320	human
O	321	330	epidermal
O	331	337	growth
O	338	344	factor
O	345	353	receptor
O	354	355	2
O	355	356	-
O	356	364	positive
O	365	375	metastatic
O	376	382	breast
O	383	389	cancer
O	390	399	receiving
O	400	409	lapatinib
O	409	410	-
O	410	422	capecitabine
O	423	425	or
O	426	437	trastuzumab
O	437	438	-
O	438	450	capecitabine
O	450	451	.

B-eligibility	452	460	Patients
I-eligibility	461	468	without
I-eligibility	469	477	baseline
I-eligibility	478	481	CNS
I-eligibility	482	492	metastases
O	493	497	were
O	498	506	randomly
O	507	515	assigned
O	516	517	(
O	517	518	1
O	518	519	:
O	519	520	1
O	520	521	)
O	522	524	to
O	525	532	receive
O	533	542	lapatinib
O	542	543	-
O	543	555	capecitabine
O	556	557	(
O	557	566	lapatinib
O	567	568	1
O	568	569	,
O	569	572	250
O	573	575	mg
O	576	579	per
O	580	583	day
O	583	584	;
O	585	597	capecitabine
O	598	599	2
O	599	600	,
O	600	603	000
O	604	606	mg
O	606	607	/
O	607	608	m
O	608	609	(
O	609	610	2
O	610	611	)
O	612	615	per
O	616	619	day
O	620	622	on
O	623	627	days
O	628	629	1
O	630	632	to
O	633	635	14
O	636	641	every
O	642	644	21
O	645	649	days
O	649	650	)
O	651	653	or
O	654	665	trastuzumab
O	665	666	-
O	666	678	capecitabine
O	679	680	(
O	680	691	trastuzumab
O	692	699	loading
O	700	704	dose
O	705	707	of
O	708	709	8
O	710	712	mg
O	712	713	/
O	713	715	kg
O	716	724	followed
O	725	727	by
O	728	730	an
O	731	739	infusion
O	740	742	of
O	743	744	6
O	745	747	mg
O	747	748	/
O	748	750	kg
O	751	756	every
O	757	758	3
O	759	764	weeks
O	764	765	;
O	766	778	capecitabine
O	779	780	2
O	780	781	,
O	781	784	500
O	785	787	mg
O	787	788	/
O	788	789	m
O	789	790	(
O	790	791	2
O	791	792	)
O	793	796	per
O	797	800	day
O	801	803	on
O	804	808	days
O	809	810	1
O	811	813	to
O	814	816	14
O	817	822	every
O	823	825	21
O	826	830	days
O	830	831	)
O	831	832	.

O	833	836	The
O	837	844	primary
O	845	848	end
O	849	854	point
O	855	858	was
B-outcome-Measure	859	868	incidence
I-outcome-Measure	869	871	of
I-outcome-Measure	872	875	CNS
I-outcome-Measure	876	886	metastases
O	887	889	as
O	890	895	first
O	896	900	site
O	901	903	of
O	904	911	relapse
O	911	912	.

O	913	922	Secondary
O	923	926	end
O	927	933	points
O	934	942	included
B-outcome-Measure	943	954	progression
I-outcome-Measure	954	955	-
I-outcome-Measure	955	959	free
I-outcome-Measure	960	968	survival
I-outcome-Measure	969	970	(
I-outcome-Measure	970	973	PFS
I-outcome-Measure	973	974	)
O	975	978	and
B-outcome-Measure	979	986	overall
I-outcome-Measure	987	995	survival
I-outcome-Measure	996	997	(
I-outcome-Measure	997	999	OS
I-outcome-Measure	999	1000	)
O	1000	1001	.

O	1002	1005	The
O	1006	1011	study
O	1012	1015	was
O	1016	1026	terminated
O	1027	1032	early
O	1033	1037	with
B-total-participants	1038	1041	540
O	1042	1050	enrolled
O	1051	1059	patients
O	1060	1061	(
B-intervention-participants	1061	1064	271
O	1065	1073	received
O	1074	1083	lapatinib
O	1083	1084	-
O	1084	1096	capecitabine
O	1096	1097	,
O	1098	1101	and
B-control-participants	1102	1105	269
O	1106	1114	received
O	1115	1126	trastuzumab
O	1126	1127	-
O	1127	1139	capecitabine
O	1139	1140	)
O	1140	1141	.

B-outcome	1142	1151	Incidence
I-outcome	1152	1154	of
I-outcome	1155	1158	CNS
I-outcome	1159	1169	metastases
O	1170	1172	as
O	1173	1178	first
O	1179	1183	site
O	1184	1186	of
O	1187	1194	relapse
O	1195	1198	was
B-iv-bin-percent	1199	1200	3
I-iv-bin-percent	1200	1201	%
O	1202	1203	(
B-iv-bin-abs	1203	1208	eight
O	1209	1211	of
B-intervention-participants	1212	1215	251
O	1216	1224	patients
O	1224	1225	)
O	1226	1229	for
O	1230	1239	lapatinib
O	1239	1240	-
O	1240	1252	capecitabine
O	1253	1256	and
B-cv-bin-percent	1257	1258	5
I-cv-bin-percent	1258	1259	%
O	1260	1261	(
B-cv-bin-abs	1261	1263	12
O	1264	1266	of
B-control-participants	1267	1270	250
O	1271	1279	patients
O	1279	1280	)
O	1281	1284	for
O	1285	1296	trastuzumab
O	1296	1297	-
O	1297	1309	capecitabine
O	1310	1311	(
O	1311	1320	treatment
O	1321	1332	differences
O	1332	1333	,
O	1334	1335	-
O	1335	1336	1
O	1336	1337	.
O	1337	1338	6
O	1338	1339	%
O	1339	1340	;
O	1341	1343	95
O	1343	1344	%
O	1345	1347	CI
O	1347	1348	,
O	1349	1350	-
O	1350	1351	2
O	1351	1352	%
O	1353	1355	to
O	1356	1357	5
O	1357	1358	%
O	1358	1359	;
O	1360	1361	P
O	1362	1363	=
O	1364	1365	.
O	1365	1368	360
O	1368	1369	)
O	1369	1370	.

B-outcome	1371	1374	PFS
O	1375	1378	and
B-outcome	1379	1381	OS
O	1382	1386	were
O	1387	1393	longer
O	1394	1398	with
O	1399	1410	trastuzumab
O	1410	1411	-
O	1411	1423	capecitabine
O	1424	1430	versus
O	1431	1440	lapatinib
O	1440	1441	-
O	1441	1453	capecitabine
O	1454	1455	(
O	1455	1461	hazard
O	1462	1467	ratio
O	1468	1469	[
O	1469	1471	HR
O	1471	1472	]
O	1473	1476	for
O	1477	1480	PFS
O	1480	1481	,
O	1482	1483	1
O	1483	1484	.
O	1484	1486	30
O	1486	1487	;
O	1488	1490	95
O	1490	1491	%
O	1492	1494	CI
O	1494	1495	,
O	1496	1497	1
O	1497	1498	.
O	1498	1500	04
O	1501	1503	to
O	1504	1505	1
O	1505	1506	.
O	1506	1508	64
O	1508	1509	;
O	1510	1512	HR
O	1513	1516	for
O	1517	1519	OS
O	1519	1520	,
O	1521	1522	1
O	1522	1523	.
O	1523	1525	34
O	1525	1526	;
O	1527	1529	95
O	1529	1530	%
O	1531	1533	CI
O	1533	1534	,
O	1535	1536	0
O	1536	1537	.
O	1537	1539	95
O	1540	1542	to
O	1543	1544	1
O	1544	1545	.
O	1545	1547	64
O	1547	1548	)
O	1548	1549	.

B-outcome	1550	1557	Serious
I-outcome	1558	1565	adverse
I-outcome	1566	1572	events
O	1573	1577	were
O	1578	1586	reported
O	1587	1589	in
B-iv-bin-percent	1590	1592	13
I-iv-bin-percent	1592	1593	%
O	1594	1595	(
B-iv-bin-abs	1595	1597	34
O	1598	1600	of
B-intervention-participants	1601	1604	269
O	1605	1613	patients
O	1613	1614	)
O	1615	1618	and
B-cv-bin-percent	1619	1621	17
I-cv-bin-percent	1621	1622	%
O	1623	1624	(
B-cv-bin-abs	1624	1626	45
O	1627	1629	of
B-control-participants	1630	1633	267
O	1634	1642	patients
O	1642	1643	)
O	1644	1646	of
O	1647	1655	patients
O	1656	1658	in
O	1659	1662	the
O	1663	1672	lapatinib
O	1672	1673	-
O	1673	1685	capecitabine
O	1686	1689	and
O	1690	1701	trastuzumab
O	1701	1702	-
O	1702	1714	capecitabine
O	1715	1719	arms
O	1719	1720	,
O	1721	1733	respectively
O	1733	1734	.

O	1735	1742	CEREBEL
O	1743	1745	is
O	1746	1758	inconclusive
O	1759	1762	for
O	1763	1766	the
O	1767	1774	primary
O	1775	1778	end
O	1779	1784	point
O	1784	1785	,
O	1786	1789	and
O	1790	1792	no
O	1793	1803	difference
O	1804	1807	was
O	1808	1816	detected
O	1817	1824	between
O	1825	1833	lapatinb
O	1833	1834	-
O	1834	1846	capecitabine
O	1847	1850	and
O	1851	1862	trastuzumab
O	1862	1863	-
O	1863	1875	capecitabine
O	1876	1879	for
O	1880	1883	the
B-outcome	1884	1893	incidence
I-outcome	1894	1896	of
I-outcome	1897	1900	CNS
I-outcome	1901	1911	metastases
O	1911	1912	.

O	1913	1914	A
O	1915	1921	better
O	1922	1929	outcome
O	1930	1933	was
O	1934	1942	observed
O	1943	1947	with
O	1948	1959	trastuzumab
O	1959	1960	-
O	1960	1972	capecitabine
O	1973	1975	in
O	1976	1979	the
O	1980	1987	overall
O	1988	1998	population
O	1998	1999	.

O	2000	2007	However
O	2007	2008	,
O	2009	2018	lapatinib
O	2018	2019	-
O	2019	2031	capecitabine
O	2032	2040	efficacy
O	2041	2044	may
O	2045	2049	have
O	2050	2054	been
O	2055	2063	affected
O	2064	2066	by
O	2067	2075	previous
O	2076	2084	exposure
O	2085	2087	to
O	2088	2089	a
O	2090	2101	trastuzumab
O	2102	2109	regimen
O	2110	2113	and
O	2113	2114	/
O	2114	2116	or
O	2117	2121	when
O	2122	2131	treatment
O	2132	2135	was
O	2136	2141	given
O	2142	2144	as
O	2145	2150	first
O	2150	2151	-
O	2152	2154	or
O	2155	2161	second
O	2161	2162	-
O	2162	2166	line
O	2167	2174	therapy
O	2175	2177	in
O	2178	2181	the
O	2182	2192	metastatic
O	2193	2200	setting
O	2200	2201	.
